Literature DB >> 23222895

Pretransplantation α-fetoprotein slope and milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation.

Teodora C Dumitra1, Sinziana Dumitra, Peter P Metrakos, Jeffrey S Barkun, Prosanto Chaudhury, Marc Deschênes, Steven Paraskevas, Mazen Hassanain, Jean I Tchervenkov.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a major cause of orthotropic liver transplantations (OLT). However, tumor recurrence remains a concern. Our group has shown that a rising natural α-fetoprotein (AFP) slope (NAS) correlates with tumor characteristics. We want to assess if a rising NAS predicts tumor recurrence.
METHODS: We reviewed first OLT for HCC (n=144) at our center from 1992 to 2010. Patients with less than two AFP values before treatment were excluded (n=52). A rising NAS (>0.1 μg/L/day) was found in 28 patients whereas 64 presented a stable or dropping NAS. Demographics, pre-OLT therapy, and tumor characteristics were collected. Statistical analysis was performed using ANOVA, chi-square or Fisher's test, and logistic regression for recurrence after OLT.
RESULTS: Demographics were similar among the recurrence (n=12) and nonrecurrence (n=80) groups. Patients who recurred received more treatment (P=0.017), had a higher number of lesions (P=0.025), a greater total tumor size (P=0.001), and a higher incidence of microvascular invasion (P=0.013). More patients exceeded the Milan criteria (75.0% vs. 31.3%, odds ratio [OR] 6.60, 95% confidence interval [CI] 1.45-4.05, P=0.008) and had a rising NAS (58.3% vs. 26.3%, OR 3.20, 95% CI 1.11-9.22, P=0.024) among the recurrence group. NAS was also a strong predictor of microvascular invasion (P=0.040). After correcting for age and sex, both a rising NAS (OR 3.98, 95% CI 1.01-15.81, P=0.039) and nonadherence to Milan criteria (OR 5.69, 95% CI 1.14-28.38, P=0.034) were strong predictors of recurrence after OLT.
CONCLUSION: The NAS is a predictor of microvascular invasion, a finding exclusive to pathology and in itself a predictor of HCC recurrence after OLT. The NAS and Milan criteria are good predictors of recurrence. These results encourage a frequent monitoring of AFP variations before OLT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23222895     DOI: 10.1097/TP.0b013e31827743d7

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

1.  Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.

Authors:  Michał Grąt; Oskar Kornasiewicz; Zbigniew Lewandowski; Wacław Hołówko; Karolina Grąt; Konrad Kobryń; Waldemar Patkowski; Krzysztof Zieniewicz; Marek Krawczyk
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

2.  Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Roongruedee Chaiteerakij; Xiaodan Zhang; Benyam D Addissie; Essa A Mohamed; William S Harmsen; Paul J Theobald; Brian E Peters; Joseph G Balsanek; Melissa M Ward; Nasra H Giama; Catherine D Moser; Abdul M Oseini; Naoki Umeda; Sudhakar Venkatesh; Denise M Harnois; Michael R Charlton; Hiroyuki Yamada; Shinji Satomura; Alicia Algeciras-Schimnich; Melissa R Snyder; Terry M Therneau; Lewis R Roberts
Journal:  Liver Transpl       Date:  2015-05       Impact factor: 5.799

Review 3.  Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma.

Authors:  Bérénice Charrière; Charlotte Maulat; Bertrand Suc; Fabrice Muscari
Journal:  World J Hepatol       Date:  2016-07-28

4.  Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.

Authors:  Bilal Hameed; Neil Mehta; Gonzalo Sapisochin; John P Roberts; Francis Y Yao
Journal:  Liver Transpl       Date:  2014-07-12       Impact factor: 5.799

Review 5.  Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation.

Authors:  Russell E Rosenblatt; Zaid H Tafesh; Karim J Halazun
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-21

6.  Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.

Authors:  Asmaa I Gomaa; Alzhraa Al-Khatib; Wael Abdel-Razek; Mohammed Saad Hashim; Imam Waked
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

Review 7.  Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients.

Authors:  Xiang-Qian Gu; Wei-Ping Zheng; Da-Hong Teng; Ji-San Sun; Hong Zheng
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 8.  Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.

Authors:  Taizo Hibi; Osamu Itano; Masahiro Shinoda; Yuko Kitagawa
Journal:  Surg Today       Date:  2016-04-29       Impact factor: 2.549

9.  Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging?

Authors:  Maria E Lozada; Roongruedee Chaiteerakij; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2015-06

10.  Selection tool alpha-fetoprotein for patients waiting for liver transplantation: How to easily manage a fractal algorithm.

Authors:  Quirino Lai; Giovanni Battista Levi Sandri; Jan Lerut
Journal:  World J Hepatol       Date:  2015-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.